Zacks Research Estimates Perrigo’s Q1 Earnings (NYSE:PRGO)

Perrigo Company plc (NYSE:PRGO) – Equities research analysts at Zacks Research upped their Q1 2027 earnings estimates for Perrigo in a report released on Monday, February 16th. Zacks Research analyst Team now expects that the company will post earnings per share of $0.82 for the quarter, up from their previous estimate of $0.81. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Perrigo’s current full-year earnings is $2.56 per share.

Several other brokerages also recently commented on PRGO. Weiss Ratings reiterated a “sell (d+)” rating on shares of Perrigo in a report on Monday, December 22nd. Wall Street Zen cut shares of Perrigo from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Argus upgraded shares of Perrigo to a “hold” rating in a research note on Wednesday, January 14th. Jefferies Financial Group dropped their price target on shares of Perrigo from $27.00 to $23.00 and set a “hold” rating on the stock in a research note on Monday, October 27th. Finally, Canaccord Genuity Group decreased their price objective on shares of Perrigo from $40.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, November 6th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $20.33.

Perrigo Trading Up 1.1%

Shares of PRGO opened at $14.61 on Wednesday. Perrigo has a 12 month low of $12.17 and a 12 month high of $30.93. The stock’s 50-day moving average is $14.23 and its two-hundred day moving average is $17.92. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.51 and a quick ratio of 1.44. The stock has a market cap of $2.01 billion, a PE ratio of -38.43, a P/E/G ratio of 1.30 and a beta of 0.39.

Institutional Trading of Perrigo

Institutional investors and hedge funds have recently modified their holdings of the business. EverSource Wealth Advisors LLC lifted its holdings in shares of Perrigo by 116.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock worth $26,000 after purchasing an additional 1,014 shares during the last quarter. Geneos Wealth Management Inc. raised its holdings in shares of Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after buying an additional 786 shares during the last quarter. UMB Bank n.a. boosted its position in shares of Perrigo by 161.5% during the fourth quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock worth $27,000 after buying an additional 1,213 shares during the period. Huntington National Bank grew its holdings in Perrigo by 237.8% in the 2nd quarter. Huntington National Bank now owns 1,054 shares of the company’s stock worth $28,000 after buying an additional 742 shares in the last quarter. Finally, Meeder Asset Management Inc. acquired a new stake in Perrigo in the 4th quarter valued at approximately $28,000. 95.91% of the stock is owned by institutional investors and hedge funds.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.